Creathor backs CryoTherapeutics' €5.2m round

Existing investors NRW Bank, Peppermint CBF, High-Tech Gründerfonds (HTGF), Getz Brothers, Kreditanstalt für Wiederaufbau (KfW) and business angels committed alongside Creathor.

The financing will be used for the clinical trial of CryoTherapeutics' catheter-based heart attack treatment in a clinical trial, with the goal of achieving market approval in Europe.

Creathor manages €180m across three funds. The latest one was launched in 2011 and has a volume of €80m. The VC invests up to €10m over the entire investment period, and between €100,000-3m during a single round.

Previous funding
CryoTherapeutics raised a €3m series-A from HTGF, Peppermint Venture Partners and NRW Bank in March 2013.

In May 2014, Peppermint led a €3.5m extension for CryoTherapeutics' series-A financing round, alongside existing backers. Rainer Christine Asset Management, Getz Brothers and KfW also took part in the extension.

Company
Founded in 2009 and based in Cologne, CryoTherapeutics was established by a team of entrepreneurs from the UK, the US and Canada, and is focusing on the development of a treatment for patients with acute coronary syndromes and myocardial infarction. The developers hope the application can avoid the use of intravascular stents or scaffolds, thus maintaining vascular function in the treated vessel.

People
Creathor Ventures – Aristotelis Nastos (partner).
CryoTherapeutics – John Yianni (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture